Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy

Neuroscience Letters

Volumn 505, Issue 3, 2011, Pages 223-227

  Nodera, Hiroyuki ^a   Spieker, Andrew ^a   Sung, Minhee ^a   Rutkove, Seward ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cisplatin; Kv7 channel; Neuroprotection; Peripheral neuropathy; Retigabine

Indexed keywords

CISPLATIN; RETIGABINE; SODIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CONTROLLED STUDY; DOWN REGULATION; DRUG SCREENING; HYPERPOLARIZATION; MALE; MEMBRANE DEPOLARIZATION; MOUSE; NERVE FIBER; NEUROPROTECTION; NONHUMAN; NOTE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SODIUM CURRENT;

ACTION POTENTIALS; ANIMALS; CARBAMATES; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; NEURAL CONDUCTION; NEUROPROTECTIVE AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; PHENYLENEDIAMINES; POTASSIUM CHANNEL BLOCKERS; TIME FACTORS;

EID: 83555164644     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.09.013     Document Type: Note

References (29)

1. Albers J.W., Chaudhry V., Cavaletti G., Donehower R.C. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst. Rev. 2011, 2:CD005228.
2. Boscia F., Annunziato L., Taglialatela M. Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharmacology 2006, 51:283-294.
3. Bostock H., Cikurel K., Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998, 21:137-158.
4. Brown D.A., Passmore G.M. Neural KCNQ (Kv7) channels. Br. J. Pharmacol. 2009, 156:1185-1195.
5. 2+-ATPase with the reversal of cisplatin ototoxicity induced by d-methionine in guinea pigs. Hear. Res. 2005, 205:102-109.
6. Descoeur J., Pereira V., Pizzoccaro A., Francois A., Ling B., Maffre V., Couette B., Busserolles J., Courteix C., Noel J., Lazdunski M., Eschalier A., Authier N., Bourinet E. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol. Med. 2011, 3:266-278.
7. Franssen H., Gebbink T.A., Wokke J.H., van den Berg L.H., van Schelven L.J. Is cold paresis related to axonal depolarization?. J. Peripher. Nerv. Syst. 2010, 15:227-237.
8. Gauchan P., Andoh T., Kato A., Kuraishi Y. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci. Lett. 2009, 458:93-95.
9. Kiernan M., Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 2000, 123(Pt 12):2542-2551.
10. Kiernan M., Burke D., Andersen K., Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000, 23:399-409.
11. Krarup-Hansen A., Helweg-Larsen S., Schmalbruch H., Rorth M., Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007, 130:1076-1088.
12. Kristensen L.V., Sandager-Nielsen K., Hansen H.H. Kv7 (KCNQ) channel openers induce hypothermia in the mouse. Neurosci. Lett. 2011, 488:178-182.
13. Lassmann H. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. Exp. Neurol. 2010, 225:2-8.
14. McWhinney S.R., Goldberg R.M., McLeod H.L. Platinum neurotoxicity pharmacogenetics. Mol. Cancer Ther. 2009, 8:10-16.
15. Moldovan M., Alvarez S., Krarup C. Motor axon excitability during Wallerian degeneration. Brain 2009, 132:511-523.
16. Moldovan M., Sorensen J., Krarup C. Comparison of the fastest regenerating motor and sensory myelinated axons in the same peripheral nerve. Brain 2006, 129:2471-2483.
17. Mori A., Nodera H., Shibuta Y., Okita T., Bostock H., Kaji R. Threshold-dependent effects on peripheral nerve in vivo excitability properties in the rat. Neurosci. Lett. 2010, 468:248-253.
18. Nodera H., Kaji R. Nerve excitability testing and its clinical application to neuromuscular diseases. Clin. Neurophysiol. 2006, 117:1902-1916.
19. Rose K., Ooi L., Dalle C., Robertson B., Wood I.C., Gamper N. Transcriptional repression of the M channel subunit Kv7.2 in chronic nerve injury. Pain 2011, 152:742-754.
20. Rundfeldt C., Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000, 50:1063-1070.
21. Sattler M.B., Williams S.K., Neusch C., Otto M., Pehlke J.R., Bahr M., Diem R. Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis. Am. J. Pathol. 2008, 173:1496-1507.
22. + current regulating excitability in the rat node of Ranvier. J. Physiol. 2006, 573:17-34.
23. Sittl R., Carr R.W., Fleckenstein J., Grafe P. Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy. Neurotoxicology 2010, 31:694-700.
24. Sittl R., Carr R.W., Schwarz J.R., Grafe P. The Kv7 potassium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated rat sural nerve. J. Peripher. Nerv. Syst. 2010, 15:63-72.
25. Ta L.E., Bieber A.J., Carlton S.M., Loprinzi C.L., Low P.A., Windebank A.J. Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol. Pain 2010, 6:15.
26. Thompson S.W., Davis L.E., Kornfeld M., Hilgers R.D., Standefer J.C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984, 54:1269-1275.
27. Tomaszewski A., Busselberg D. Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats. Neurotoxicology 2007, 28:49-58.
28. Waxman S. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat. Clin. Pract. Neurol. 2008, 4:159-169.
29. Windebank A.J., Grisold W. Chemotherapy-induced neuropathy. J. Peripher. Nerv. Syst. 2008, 13:27-46.